Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Treatment

A New Software To Assess Driving Behaviour And Driving Risks
One of the aims imposed by the European Union in 2004 is to reduce the number of traffic accidents. However, despite the measures taken by the different administrations and the consequent decrease in the number of accidents, the results for 2010 are not close to those set by Europe. Gerardo Reveriego, a young researcher of the University of Mç¡laga, has designed software that informs drivers of the risk situations s/he has while driving. This allows drivers to self-assess themselves and improve their driving behaviour.
generic viagra online
Formula 1 Team Races Against Hunger
Panasonic Toyota Racing Formula 1 drivers will team up with the
News of the day
NYC Law Makes It Easier To Press Charges Against Antiabortion Protesters Outside Clinics
A New York City law that will go into effect in July could make it easier for antiabortion-rights protesters to be arrested for restricting access to abortion clinics or harassing people trying to enter the facilities, the New York Times reports. Current law allows authorities to make arrests only if the person directly affected, such as a woman entering a clinic, is willing to press charges. However, the new law would allow third parties, such as clinic workers, to press charges if they witnessed the activity, the Times reports. New York City"s Dr. Emily"s Women"s Health Center and NARAL Pro-Choice New York spearheaded efforts to pass the legislation in response to antiabortion-rights demonstrators who target women on their way to clinics and attempt to persuade them to carry their pregnancies to term. Clinic workers report that the protesters also have harassed women as they left the subway or surrounded them as they walked to the clinic. New York City Mayor Michael Bloomberg signed the law in April. Joan Malin, president and CEO of Planned Parenthood of New York City, said the group is "not against people demonstrating. But there is a line between freedom of speech and harassment and bullying" (Bosman, New York Times, 6/6).
Public Health

Drug Combination Improves Outcome For Advanced Non-Small Cell Lung Cancer

A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III "ATLAS" trial were presented today by Dr. Vincent Miller of Memorial Sloan-Kettering Cancer Center (MSKCC) at the American Society of Clinical Oncology Annual Meeting. The goal of the study was to determine whether adding erlotinib (Tarceva®), a targeted agent, to maintenance therapy with bevacizumab (Avastin®), an agent commonly used as a component of treatment for advanced NSCLC would delay disease progression. Maintenance therapy involves using one or more agents of a chemotherapy regimen, but not the entire regimen, to delay disease progression and possibly improve survival after patients have previously received stronger standard chemotherapy, which can have significant side effects. "This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," said Dr. Miller, a thoracic oncologist at MSKCC and one of the study"s lead authors. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research," Dr. Miller added. In total, 768 patients were randomized to receive bevacizumab plus erlotinib or bevacizumab plus placebo after initial cytotoxic chemotherapy with bevacizumab. There was a 29 percent reduction in the risk of progression for those patients treated with erlotinib, and the median progression-free survival (the time it took for the cancer to get worse) was 4.8 months for the combination versus 3.7 months for the bevacizumab-placebo group. Because a statistically significant improvement in efficacy was found in the erlotinib group, the trial was stopped early. The combination was also found to be safe and well tolerated. Bevacizumab and erlotinib are classified as targeted therapies - agents that block tumor growth by interfering with specific molecules critical to the survival of cancer cells. Individually, both drugs have shown promise in previous studies in the treatment of NSCLC. According to the National Cancer Institute, in 2008 the estimated number of new lung cancer cases (non-small cell and small cell combined) was 215,000 and the number of deaths was 161,840. Non-small cell lung cancer is the most common among all lung cancers and is usually associated with a history of tobacco use. Courtney DeNicola Memorial Sloan-Kettering Cancer Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009